Pepto-Bismol: 5 Symptoms Relief – Pink Does More Than You Think

News

Pepto-Bismol: 5 Symptoms Relief – Pink Does More Than You Think

2025-02-04 15:02 Last Updated At：15:20

LONDON--(BUSINESS WIRE)--Feb 4, 2025--

Did you know that 60% of adults in the UK face gastrointestinal (GI) issues* each year? Furthermore, 40% of those affected can experience multiple symptoms during a single occurrence, leading to embarrassment and discomfort. In response to this widespread challenge, we’re excited to share that Pepto-Bismol Oral Suspension, your go-to solution for tummy troubles, is back in the UK, and now available with a new classification change from P to GSL for easier access!

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203539982/en/

Pepto-Bismol, with the active ingredient Bismuth Subsalicylate, provides effective relief for five common digestive issues: Nausea, Heartburn, Indigestion, Upset Stomach, and Diarrhea. This formulation works by coating the stomach lining and lower gut, soothing irritation and discomfort that often arise from overindulgence in food and drink.

The mechanism of action (MOA) of Bismuth Subsalicylate includes:

Pepto-Bismol is easy to use: recommended dosing is 1 dose (30 mL) every 30-60 minutes as needed, with a maximum of 8 doses in 24 hours. The attached dosing cup ensures accurate measurement for optimal relief.

Call to Action: Encourage your patients not to let digestive issues hold them back. With Pepto-Bismol, they can swiftly return to their daily activities with confidence.

Disclaimer: Pepto-Bismol 17.5 mg/ml Oral Suspension. Active ingredient: Each ml of suspension contains 17.5 mg Bismuth Subsalicylate. One dose of 30 ml contains 525 mg Bismuth Subsalicylate. Indicated in adults and adolescents aged 16 years and over for symptomatic relief of heartburn, indigestion, nausea and upset stomach (due to overindulgence in food and drink). Also controls diarrhoea. MAH: Procter & Gamble (Health & Beauty Care) Ltd. The Heights, Brooklands, Weybridge. Surrey, KT13 0XP, UK. Supply classification: GSL. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: https://mhraproducts4853.blob.core.windows.net/docs/64a487d27c6660c75e6ba370a49398fca93bb2a6

Availability: Pepto-Bismol is now available on the shelves of your supermarkets, online and also in pharmacies, making it easier for everyone!

*Pepto-related symptoms: Nausea, Heartburn, Indigestion, Upset Stomach and Diarrhea.

About Pepto-Bismol: Pepto-Bismol is a Procter & Gamble brand! Pepto-Bismol provides soothing relief for five different stomach symptoms: nausea, heartburn, indigestion, upset stomach and diarrhoea. For adults and adolescents aged 16 years and older, Pepto-Bismol is currently available in an oral suspension form, in 3 different sizes: 120ml, 240ml and 480ml bottles.

Box Office: ‘Mandalorian and Grogu’ tops charts and ‘Obsession’ grows in second weekend

After nearly seven years away from the big screen, a new Star Wars movie drew healthy but not record-breaking crowds to global theaters this weekend. According to studio estimates on Sunday, “Star Wars: The Mandalorian and Grogu” made $82 million in ticket sales from 4,300 theaters in the U.S. and Canada. By the end of Monday’s Memorial Day holiday, it’s expected to have earned $102 million domestically and $165 million globally.

It exceeded opening weekend expectations for the movie, a continuation of Disney+ spinoff series “The Mandalorian,” but it’s also on the low end of Disney-era Star Wars releases, closer to “Solo: A Star Wars Story,” which made $103 million over the four-day Memorial Day frame in 2018. While “Solo” was considered a disaster, the metrics around “The Mandalorian and Grogu” are a little different.

The production budget for “Solo” was in the $300 million range, while “The Mandalorian and Grogu” was made for significantly less — a reported $165 million, not accounting for marketing and promotion costs. It makes the journey to profitability more likely, especially when factoring in positive audience scores. Although critics were mixed to negative on the movie (it currently carries a 63% on Rotten Tomatoes), ticket buyers overall gave it an A- CinemaScore. Boys under the age of 13 are especially high on the movie: They gave it an A CinemaScore and a perfect five on PostTrak. Parents also gave it a five out of five.

The Jon Favreau-directed movie stars Pedro Pascal as the titular bounty hunter and puts him and his tiny green companion on a mission to save Jabba’s son Rotta the Hutt, who is voiced by Jeremy Allen White.

“Star Wars: The Mandalorian and Grogu” could also be graded on a bit of a curve because of the streaming component, both that it started as a series, and that it will eventually end up as a value add on Disney+, which was only about a month old when the last Star Wars movie, “The Rise of Skywalker,” debuted in December 2019.

Star Wars as a brand is in a time of transition under its new leadership team of Dave Filoni and Lynwen Brennan; Earlier this year it was announced that Lucasfilm president Kathleen Kennedy, who produced “Star Wars: The Mandalorian and Grogu,” was stepping down after 13 years. The question for the industry is whether audience interest in Star Wars on the big screen might have cooled slightly, and if next year’s “Star Wars: Starfighter,” starring Ryan Gosling, will provide a definitive answer. Until then, the hope is that strong audience and exit scores will propel word-of-mouth generated enthusiasm in the coming weeks.

Word-of-mouth certainly helped Curry Barker’s relationship horror movie “Obsession” defy the standard box office trajectory and do better business in its second weekend. The Focus Features had an astonishing 30% uptick in ticket sales, earning $22.4 million from 2,655 theaters. The studio, which acquired the microbudget movie for some $15 million, is projecting that it will have made $28.2 million by the end of Monday, bringing its running total to $58.5 million. It snagged the second-place spot, while “Michael” landed in third place with $20 million for the three-day weekend. The Michael Jackson biopic has now earned $782.4 million.

“Obsession” also did better than the new horror movie “Passenger,” a Paramount Pictures release with Melissa Leo, which grossed an estimated $8.7 million from 2,534 locations. It’s expected to earn $10.5 million over its first four days. The movie received poor reviews from both critics (44% on Rotten Tomatoes) and audiences (B- Cinema Score).

The mix of movies this year didn’t hold a candle to last year’s record Memorial Day weekend, which was led by Disney’s live-action “Lilo & Stitch” and “Mission: Impossible — The Final Reckoning.” The overall four-day frame this year will net out around $211 million, down about 36% from last year’s $330 million. It’s also far from the disastrous 2024 Memorial Day weekend box office, a 30-year low, when “Furiosa: A Mad Max Saga” opened.